✦ LIBER ✦

Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve

✍ Scribed by W. Kern; J. Braess; S. Friedrichsen; C. C. Kaufmann; E. Schleyer; W. Hiddemann

Book ID: 106124549
Publisher: Springer-Verlag
Year: 2001
Tongue: English
Weight: 95 KB
Volume: 127
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s004320000169

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

161 Carboplatin prescribed in mg/m2 in p

161 Carboplatin prescribed in mg/m2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival and hematological toxicity?

✍ Paesmans, M.; Sculier, J.P.; Thiriaux, J.; Bureau, G.; Giner, V.; Efremidis, A.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 319 KB

The impact of age on toxicity, response

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

✍ Thomas A. Hensing; Amy H. Peterman; Michael J. Schell; Ji-Hyun Lee; Mark A. Soci 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND The optimal treatment strategy for elderly patients with advanced nonsmall cell lung carcinoma has not been defined to date. The authors performed a retrospective analysis of a Phase III trial that treated patients who had Stage IIIB or IV nonsmall cell lung carcinoma wit

92 POSTER Effects of AZD2171 on pharmaco

92 POSTER Effects of AZD2171 on pharmacokinetics (PK) of carboplatin (C) and paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; W. Zhang; S. Lauri; A. Arnold; I. Gauthier; G. Goss; P. Ellis; F. Sheph 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB